Lukasz Kuzma/LinkedIn
Feb 16, 2026, 14:44
Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES
Lukasz Kuzma, Research Professor at University of Liverpool, shared a post on X about a recent article he and his colleague co-authored, adding:
“In our NEJM editorial with ESC Stroke Chair, we highlight the first RCT in AF more than 1 year after DES showing that NOAC monotherapy was not noninferior and statistically superior to NOAC plus clopidogrel for net adverse clinical events also with less bleeding.”
Title: Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents
Authors: Gregory Y.H. Lip and Lukasz Kuzma
Read the Full Article on The New England Journal of Medicine.
Stay updated with Hemostasis Today.
-
Jul 11, 2026, 15:22Cécile Denis: A Unique Opportunity for Emerging Hemostasis Leaders
-
Jul 11, 2026, 15:03Dino Mehic: Paris Welcomes the Global Hemostasis Community at ISTH 2026
-
Jul 11, 2026, 14:55Carsten Deppermann: An Inspiring Perspective on Scientific Discovery
-
Jul 11, 2026, 14:47Isabella Presch: Arrived in Amazing Paris For ISTH 2026
-
Jul 11, 2026, 14:12Riten Kumar: The Opening Day Experience at ISTH 2026
-
Jul 11, 2026, 13:44Mary Cushman: A Decade After the RPTH Journal Launch at ISTH 2026
-
Jul 11, 2026, 11:31Acute DVT Management and the Role of Interventions Beyond Anticoagulation: Insights From ISTH 2026
-
Jul 11, 2026, 09:48Kathleen Freson: Leaving to Paris For a Sunny ISTH 2026 Meeting
-
Jul 11, 2026, 09:45Presenting New CRP-A Data at ISTH 2026 – Pplus Medical Limited